Search
Sparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnIt is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. … Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness
Flunisolide
go.drugbank.com/drugs/DB00180ApprovedFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...
Categories: Agents to Treat Airway DiseaseRanpirnase
go.drugbank.com/drugs/DB04950InvestigationalIt is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family. … One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.
Besifovir dipivoxil
go.drugbank.com/drugs/DB05020InvestigationalBesifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Perflutren
go.drugbank.com/drugs/DB00556ApprovedInvestigationalWhen exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. … Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnPatients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
BCG vaccine
go.drugbank.com/drugs/DB12768ApprovedInvestigationalWithdrawnBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.